New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1
1 gen 2016 ·
31 min. 42 sec.
Iscriviti gratuitamente
Ascolta questo episodio e molti altri. Goditi i migliori podcast su Spreaker!
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
Descrizione
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr....
mostra di più
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
mostra meno
Informazioni
| Autore | cancerGRACE |
| Sito | - |
| Tag |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
